KALA BIO, Inc. (LON: 0JQ2)
London
· Delayed Price · Currency is GBP · Price in USD 7.22
-0.45 (-5.90%)
Jan 21, 2025, 4:50 PM BST
KALA BIO Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
43
Market Cap
28.79M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 38.20B |
| GSK plc | 31.31B |
| Haleon | 11.24B |
| Smith & Nephew | 4.46B |
| ConvaTec Group | 1.74B |
| Hikma Pharmaceuticals | 2.39B |
| HUTCHMED (China) | 483.31M |
| Oxford Nanopore Technologies | 167.75M |
KALA BIO News
- 24 days ago - KALA BIO Announces $10,750,000 Private Placement - GlobeNewsWire
- 2 months ago - KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference - GlobeNewsWire
- 8 months ago - KALA BIO to Present at Jefferies Global Healthcare Conference - GlobeNewsWire
- 9 months ago - KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 10 months ago - KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update - GlobeNewsWire
- 11 months ago - KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference - GlobeNewsWire
- 1 year ago - KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 1 year ago - KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update - GlobeNewsWire